country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-183395

Copy Link Print Information

FPTI

FPTI is a SYT-SSX1 fusion protein modulator with selective cytotoxicity in SYT-SSX1-positive synovial sarcoma cells. FPTI down-regulates SYT-SSX1 expression and modulates its downstream target genes. FPTI induces apoptosis in synovial sarcoma cells. FPTI can be used for the research of synovial sarcoma.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 173374-58-8
Formel: C₁₅H₁₀FN₅
Molecular Weight:279.27

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

FPTI Chemical Structure

CAS. Nr.: 173374-58-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

In Vitro

FPTI (10-100 μM; 24-96 h) selectively reduces cell viability in SYT-SSX1-positive Yamato and ASKA synovial sarcoma cell lines with IC₅₀ values of 33 μM and 39 μM, respectively, while showing weaker activity against non-synovial sarcoma and normal cell lines^[1].
FPTI (10-40 μM; 72 h) modulates gene expression in SYT-SSX1-positive ASKA synovial sarcoma cells by downregulating SYT-SSX1 and key oncogenic downstream targets, while upregulating CDKN2A^[1].
FPTI (10-40 μM; 24 h) induces apoptotic cell death in SYT-SSX1-positive ASKA synovial sarcoma cells in a concentration-dependent manner, with greater late-stage apoptosis observed at the 40 μM IC₅₀ dose after 24 h^[1].
FPTI (10-40 μM; 72 h) induces G0-G1 cell cycle arrest and increases apoptotic sub-G0 cell population in SYT-SSX1-positive ASKA synovial sarcoma cells after 72 h, with the strongest effect observed at the 40 μM IC₅₀ dose^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

Yamato (SYT-SSX1-positive synovial sarcoma), ASKA (SYT-SSX1-positive synovial sarcoma), HEK293 (immortalized embryonic kidney), 143B (sarcoma), A673 (sarcoma)
Concentration:

10-100 μM (72 h); 40 μM (24, 48, 96 h)
Incubation Time:

24 h, 48 h, 72 h, 96 h
Result:

Reduced cell viability by 48.71% in HEK293, 67.35% in ASKA, and 72.48% in Yamato cells at 40 μM for 72 h compared to DMSO controls.
Showed insignificant cytotoxicity at 10 μM and 20 μM.
Induced cytotoxicity in HEK293 cells below 50% viability at 60, 80, 100 μM.
Showed no significant cytotoxicity in 143B or A673 cells.
Achieved IC₅₀ values of 39 μM for ASKA, 33 μM for Yamato, 66 μM for HEK293, 64 μM for 143B, and 70 μM for A673.

Real Time qPCR^[1]

Cell Line:

ASKA (SYT-SSX1-positive synovial sarcoma)
Concentration:

10 μM, 40 μM (72 h)
Incubation Time:

72 h
Result:

Downregulated expression of SYT-SSX1 and its downstream target genes cyclin D1 (CCDN1), β-catenin (CTNNB1), FZD, PDGFRA, COM1, SMARCB1, and P21 at 40 μM.
Induced dose-dependent repression of FZD, CCDN1, SMARCB1, and P21.
Downregulated EGFR and EGR1 only at 10 μM.
Upregulated CDKN2A with treatment.

Apoptosis Analysis^[1]

Cell Line:

ASKA (SYT-SSX1-positive synovial sarcoma)
Concentration:

10 μM (IC₁₀), 40 μM (IC₅₀) (24 h)
Incubation Time:

24 h
Result:

Altered cell forward and side scatter parameters compared to untreated cells.
Increased cell death to over twice the basal level at 10 μM.
Increased cell death to thrice the basal level at 40 μM.
Induced a marked increase in dual Annexin V/PI staining indicative of late apoptosis at 40 μM.

Cell Cycle Analysis^[1]

Cell Line:

ASKA (SYT-SSX1-positive synovial sarcoma)
Concentration:

10 μM (non-lethal dose), 40 μM (IC₅₀) (72 h)
Incubation Time:

72 h
Result:

Increased the sub-G0 cell population to 31.25% (from 5.385% in untreated cells) and reduced the G0-G1 population to 44.9% (from 69.1% in untreated cells) at 40 μM.
Left the S and G2/M phase populations nearly unchanged at 40 μM.
Increased the sub-G0 population to 15.3% and reduced the G0-G1 population to 53.5% at 10 μM.

Chemical Information

CAS. Nr. 173374-58-8
Molecular Weight 279.27
Formel C₁₅H₁₀FN₅
SMILES

FC1=CC=C2NC=C(C2=C1)C3=NN=NN3C4=CC=CC=C4
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Handling Instructions (2659 KB)

Verweise

[1]. Natarajan V, et al. In silico and in vitro screening of small molecule Inhibitors against SYT-SSX1 fusion protein in synovial sarcoma. Computational biology and chemistry. 2018 Dec;77:36-43. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen